Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Andreas Thess

Showing results (1-10 of 12) with videos related to

Pageof 2
Sort By:
Cellular and Molecular Life Sciences : CMLS|October 19, 2018
mRNA as novel technology for passive immunotherapyThomas Schlake, Andreas Thess, Moritz Thran, et al.
RNA Biology|October 16, 2012
Developing mRNA-vaccine technologiesThomas Schlake, Andreas Thess, Mariola Fotin-Mleczek, et al.
Biological Chemistry|September 15, 2021
Historic nucleic acids isolated by Friedrich Miescher contain RNA besides DNAAndreas Thess, Ingmar Hoerr, Benyamin Yazdan Panah, et al.
The Journal of Biological Chemistry|July 13, 2002
Specific orientation and two-dimensional crystallization of the proteasome at metal-chelating lipid interfacesAndreas Thess, Silke Hutschenreiter, Matthias Hofmann, et al.
Molecular Therapy : the Journal of the American Society of Gene Therapy|June 9, 2015
Sequence-engineered mRNA Without Chemical Nucleoside Modifications Enables an Effective Protein Therapy in Large AnimalsAndreas Thess, Stefanie Grund, Barbara L Mui, et al.
The Journal of Gene Medicine|January 21, 2012
Highly potent mRNA based cancer vaccines represent an attractive platform for combination therapies supporting an improved therapeutic effectMariola Fotin-Mleczek, Kai Zanzinger, Regina Heidenreich, et al.
Vaccines|August 26, 2022
Optimised Non-Coding Regions of mRNA SARS-CoV-2 Vaccine CV2CoV Improves Homologous and Heterologous Neutralising Antibody ResponsesNicole Roth, Jacob Schön, Donata Hoffmann, et al.
BMC Cancer|June 26, 2009
Production and characterisation of monoclonal antibodies against RAI3 and its expression in human breast cancerHannah Jörissen, Nuran Bektas, Edgar Dahl, et al.
Human Vaccines & Immunotherapeutics|August 8, 2013
A novel, disruptive vaccination technology: self-adjuvanted RNActive(®) vaccinesKarl-Josef Kallen, Regina Heidenreich, Margit Schnee, et al.
Nature Biotechnology|November 20, 2012
Protective efficacy of in vitro synthesized, specific mRNA vaccines against influenza A virus infectionBenjamin Petsch, Margit Schnee, Annette B Vogel, et al.
Pageof 2

Showing results (1-10 of 12) with videos related to

Sort By:
Pageof 2
Cellular and Molecular Life Sciences : CMLS|October 19, 2018
mRNA as novel technology for passive immunotherapyThomas Schlake, Andreas Thess, Moritz Thran, et al.
RNA Biology|October 16, 2012
Developing mRNA-vaccine technologiesThomas Schlake, Andreas Thess, Mariola Fotin-Mleczek, et al.
Biological Chemistry|September 15, 2021
Historic nucleic acids isolated by Friedrich Miescher contain RNA besides DNAAndreas Thess, Ingmar Hoerr, Benyamin Yazdan Panah, et al.
The Journal of Biological Chemistry|July 13, 2002
Specific orientation and two-dimensional crystallization of the proteasome at metal-chelating lipid interfacesAndreas Thess, Silke Hutschenreiter, Matthias Hofmann, et al.
Molecular Therapy : the Journal of the American Society of Gene Therapy|June 9, 2015
Sequence-engineered mRNA Without Chemical Nucleoside Modifications Enables an Effective Protein Therapy in Large AnimalsAndreas Thess, Stefanie Grund, Barbara L Mui, et al.
The Journal of Gene Medicine|January 21, 2012
Highly potent mRNA based cancer vaccines represent an attractive platform for combination therapies supporting an improved therapeutic effectMariola Fotin-Mleczek, Kai Zanzinger, Regina Heidenreich, et al.
Vaccines|August 26, 2022
Optimised Non-Coding Regions of mRNA SARS-CoV-2 Vaccine CV2CoV Improves Homologous and Heterologous Neutralising Antibody ResponsesNicole Roth, Jacob Schön, Donata Hoffmann, et al.
BMC Cancer|June 26, 2009
Production and characterisation of monoclonal antibodies against RAI3 and its expression in human breast cancerHannah Jörissen, Nuran Bektas, Edgar Dahl, et al.
Human Vaccines & Immunotherapeutics|August 8, 2013
A novel, disruptive vaccination technology: self-adjuvanted RNActive(®) vaccinesKarl-Josef Kallen, Regina Heidenreich, Margit Schnee, et al.
Nature Biotechnology|November 20, 2012
Protective efficacy of in vitro synthesized, specific mRNA vaccines against influenza A virus infectionBenjamin Petsch, Margit Schnee, Annette B Vogel, et al.
Pageof 2